The safety and efficacy of intra-arterial low-dose tirofiban administration during endovascular therapy in patients with large ischemic core volume
Abstract This study aimed to evaluate the safety and efficacy of intra-arterial (IA) administration of low- dose tirofiban during endovascular therapy in patients with large ischemic core volumes on initial brain CT. Patients were divided into two groups based on the use of IA tirofiban. We identifi...
| Glavni autori: | , , , , |
|---|---|
| Format: | Članak |
| Jezik: | English |
| Izdano: |
Nature Portfolio
2024-02-01
|
| Serija: | Scientific Reports |
| Teme: | |
| Online pristup: | https://doi.org/10.1038/s41598-024-53715-8 |
| _version_ | 1827327373613203456 |
|---|---|
| author | Kwang-Chun Cho Nak-Hoon Son So Hyeon Gwon Jin Wook Choi Woo Sang Jung |
| author_facet | Kwang-Chun Cho Nak-Hoon Son So Hyeon Gwon Jin Wook Choi Woo Sang Jung |
| author_sort | Kwang-Chun Cho |
| collection | DOAJ |
| description | Abstract This study aimed to evaluate the safety and efficacy of intra-arterial (IA) administration of low- dose tirofiban during endovascular therapy in patients with large ischemic core volumes on initial brain CT. Patients were divided into two groups based on the use of IA tirofiban. We identified 87 patients (16 and 71 patients in the tirofiban and no-tirofiban groups, respectively) with acute ischemic stroke due to intracranial artery occlusion who underwent endovascular therapy with a low Alberta Stroke Program Early CT scores (2–5). Multivariate logistic regression analysis revealed no association between IA tirofiban administration and serious postprocedural hemorrhagic complications (adjusted odds ratio (aOR), 0.720; 95% confidence interval (CI) 0.099–5.219; p = 0.960), any radiologic hemorrhage (aOR 0.076; 95% CI 0.003–2.323; p = 0.139), or 3-month mortality (aOR, 0.087; 95% CI 0.005–1.501; p = 0.093). However, IA tirofiban was associated with a lower 90-day mRS score (aOR, 0.197; 95% CI 0.015–1.306; p = 0.017) and change of NIHSS compared with baseline (aOR, 0.698; 95% CI 0.531–0.917; p = 0.010). IA tirofiban administration during endovascular therapy in patients with large ischemic core volumes may be effective and safe. |
| first_indexed | 2024-03-07T15:00:16Z |
| format | Article |
| id | doaj.art-43bc3dc57de64ddf859a919c1569f8a7 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-03-07T15:00:16Z |
| publishDate | 2024-02-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-43bc3dc57de64ddf859a919c1569f8a72024-03-05T19:11:27ZengNature PortfolioScientific Reports2045-23222024-02-011411610.1038/s41598-024-53715-8The safety and efficacy of intra-arterial low-dose tirofiban administration during endovascular therapy in patients with large ischemic core volumeKwang-Chun Cho0Nak-Hoon Son1So Hyeon Gwon2Jin Wook Choi3Woo Sang Jung4Department of Neurosurgery, Yongin Severance Hospital, Yonsei University College of MedicineDepartment of Statistics, Keimyung UniversityDepartment of Statistics, Keimyung UniversityDepartment of Radiology, Ajou University Hospital, Ajou University College of MedicineDepartment of Radiology, Ajou University Hospital, Ajou University College of MedicineAbstract This study aimed to evaluate the safety and efficacy of intra-arterial (IA) administration of low- dose tirofiban during endovascular therapy in patients with large ischemic core volumes on initial brain CT. Patients were divided into two groups based on the use of IA tirofiban. We identified 87 patients (16 and 71 patients in the tirofiban and no-tirofiban groups, respectively) with acute ischemic stroke due to intracranial artery occlusion who underwent endovascular therapy with a low Alberta Stroke Program Early CT scores (2–5). Multivariate logistic regression analysis revealed no association between IA tirofiban administration and serious postprocedural hemorrhagic complications (adjusted odds ratio (aOR), 0.720; 95% confidence interval (CI) 0.099–5.219; p = 0.960), any radiologic hemorrhage (aOR 0.076; 95% CI 0.003–2.323; p = 0.139), or 3-month mortality (aOR, 0.087; 95% CI 0.005–1.501; p = 0.093). However, IA tirofiban was associated with a lower 90-day mRS score (aOR, 0.197; 95% CI 0.015–1.306; p = 0.017) and change of NIHSS compared with baseline (aOR, 0.698; 95% CI 0.531–0.917; p = 0.010). IA tirofiban administration during endovascular therapy in patients with large ischemic core volumes may be effective and safe.https://doi.org/10.1038/s41598-024-53715-8Acute ischemic strokeEndovascular therapyAlberta Stroke Program Early CT ScoreTirofiban |
| spellingShingle | Kwang-Chun Cho Nak-Hoon Son So Hyeon Gwon Jin Wook Choi Woo Sang Jung The safety and efficacy of intra-arterial low-dose tirofiban administration during endovascular therapy in patients with large ischemic core volume Scientific Reports Acute ischemic stroke Endovascular therapy Alberta Stroke Program Early CT Score Tirofiban |
| title | The safety and efficacy of intra-arterial low-dose tirofiban administration during endovascular therapy in patients with large ischemic core volume |
| title_full | The safety and efficacy of intra-arterial low-dose tirofiban administration during endovascular therapy in patients with large ischemic core volume |
| title_fullStr | The safety and efficacy of intra-arterial low-dose tirofiban administration during endovascular therapy in patients with large ischemic core volume |
| title_full_unstemmed | The safety and efficacy of intra-arterial low-dose tirofiban administration during endovascular therapy in patients with large ischemic core volume |
| title_short | The safety and efficacy of intra-arterial low-dose tirofiban administration during endovascular therapy in patients with large ischemic core volume |
| title_sort | safety and efficacy of intra arterial low dose tirofiban administration during endovascular therapy in patients with large ischemic core volume |
| topic | Acute ischemic stroke Endovascular therapy Alberta Stroke Program Early CT Score Tirofiban |
| url | https://doi.org/10.1038/s41598-024-53715-8 |
| work_keys_str_mv | AT kwangchuncho thesafetyandefficacyofintraarteriallowdosetirofibanadministrationduringendovasculartherapyinpatientswithlargeischemiccorevolume AT nakhoonson thesafetyandefficacyofintraarteriallowdosetirofibanadministrationduringendovasculartherapyinpatientswithlargeischemiccorevolume AT sohyeongwon thesafetyandefficacyofintraarteriallowdosetirofibanadministrationduringendovasculartherapyinpatientswithlargeischemiccorevolume AT jinwookchoi thesafetyandefficacyofintraarteriallowdosetirofibanadministrationduringendovasculartherapyinpatientswithlargeischemiccorevolume AT woosangjung thesafetyandefficacyofintraarteriallowdosetirofibanadministrationduringendovasculartherapyinpatientswithlargeischemiccorevolume AT kwangchuncho safetyandefficacyofintraarteriallowdosetirofibanadministrationduringendovasculartherapyinpatientswithlargeischemiccorevolume AT nakhoonson safetyandefficacyofintraarteriallowdosetirofibanadministrationduringendovasculartherapyinpatientswithlargeischemiccorevolume AT sohyeongwon safetyandefficacyofintraarteriallowdosetirofibanadministrationduringendovasculartherapyinpatientswithlargeischemiccorevolume AT jinwookchoi safetyandefficacyofintraarteriallowdosetirofibanadministrationduringendovasculartherapyinpatientswithlargeischemiccorevolume AT woosangjung safetyandefficacyofintraarteriallowdosetirofibanadministrationduringendovasculartherapyinpatientswithlargeischemiccorevolume |